AGE GROUP  19-21 years 22-26 years 27-49 years 50-59 years 60-64 years  65 years Influenza *,2 Tetanus, diphtheria, pertussis (Td/Tdap) *,3 Varicella *,4    Human papillomavirus (HPV) Female *,5    Human papillomavirus (HPV) Male *,5 Zoster 6 Measles, mumps, rubella (MMR) *,7    Pneumococcal 13-valent conjugate (PCV13) *,8    Pneumococcal 23-valent polysaccharide (PPSV23) 8 Hepatitis A *,9 Hepatitis B *,10 Meningococcal 4-valent conjugate (MenACWY) or polysaccharide (MPSV4) *,11 Meningococcal B (MenB) 11 Haemophilus influenzae type b (Hib) *,12 *Covered by the Vaccine Injury Compensation Program 3 doses 1 or 3 doses depending on indication 2 or 3 doses depending on vaccine 1 or more doses depending on indication 2 or 3 doses depending on vaccine 1 dose 1 or 2 doses depending on indication 1 dose 3 doses 2 doses Substitute Tdap for Td once, then Td booster every 10 yrs 1 dose annually Recommended for all persons who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection; zoster vaccine is recommended regardless of past episode of zoster Recommended for persons with a risk factor (medical, occupational, lifestyle, or other indication) No recommendationNote: These recommendations must be read with the footnotes that follow containing number of doses, intervals between doses, and other important information.#
Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at www.vaers.hhs.gov or by telephone, 800-822-7967.
Information on how to file a Vaccine Injury Compensation Program claim is available at www.hrsa.gov/vaccinecompensation or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005;telephone, 202-357-6400.
Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at www.cdc.gov/vaccines or from the CDC-INFO Contact Center at 800-CDC-  in English and Spanish, 8:00 a.m. -8:00 p.m. Eastern Time, Monday -Friday, excluding holidays.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
The recommendations in this schedule were approved by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), the America College of Physicians (ACP), the American College of Obstetricians and Gynecologists (ACOG) and the American College of Nurse-Midwives (ACNM).

# VACCINE  INDICATION  Pregnancy
Immunocompromising conditions (excluding HIV infection) 4,6,7,8,13 HIV infection CD4+ count (cells/L) 4,6,7,8,13  Influenza *,2 Tetanus, diphtheria, pertussis (Td/Tdap) *,3
Varicella *,4 Human papillomavirus (HPV) Female *,5 Human papillomavirus (HPV) Male *,5 Zoster 6
Measles, mumps, rubella (MMR) *,7 Pneumococcal 13-valent conjugate (PCV13) *,8 Pneumococcal polysaccharide (PPSV23) 8 Hepatitis A *,9 Hepatitis B *,10 Meningococcal 4-valent conjugate (MenACWY) or polysaccharide (MPSV4) *,11 Meningococcal B (MenB) 11
Haemophilus influenzae type b (Hib) *,12 These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly recommended for adults aged 19 years, as of February 2016. For all vaccines being recommended on the Adult Immunization Schedule: a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/index.html). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

# dose 3 doses post-HSCT recipients only
Recommended for all persons who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection; zoster vaccine is recommended regardless of past episode of zoster vaccine status is unknown should receive a dose of Tdap followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. Tdap can be administered regardless of interval since the most recent tetanus or diphtheriatoxoid-containing vaccine. - Adults with an unknown or incomplete history of completing a 3-dose primary vaccination series with Td-containing vaccines should begin or complete a primary vaccination series including a Tdap dose. - For unvaccinated adults, administer the first 2 doses at least 4 weeks apart and the third dose 6-12 months after the second. - For incompletely vaccinated (i.e., less than 3 doses) adults, administer remaining doses. - Refer to the ACIP statement for recommendations for administering Td/Tdap as prophylaxis in wound management (see footnote 1).

# Varicella vaccination
- All adults without evidence of immunity to varicella (as defined below) should receive 2 doses of single-antigen varicella vaccine or a second dose if they have received only 1 dose. - Vaccination should be emphasized for those who have close contact with persons at high risk for severe disease (e.g., health care personnel and family contacts of persons with immunocompromising conditions) or are at high risk for exposure or transmission (e.g., teachers; child care employees; residents and staff members of institutional settings, including correctional institutions; college students; military personnel; adolescents and adults living in households with children; nonpregnant women of childbearing age; and international travelers). - Pregnant women should be assessed for evidence of varicella immunity. Women who do not have evidence of immunity should receive the first dose of varicella vaccine upon completion or termination of pregnancy and before discharge from the health care facility. The second dose should be administered 4-8 weeks after the first dose. - Evidence of immunity to varicella in adults includes any of the following: -documentation of 2 doses of varicella vaccine at least 4 weeks apart; -U.S.-born before 1980, except health care personnel and pregnant women; -history of varicella based on diagnosis or verification of varicella disease by a health care provider; -history of herpes zoster based on diagnosis or verification of herpes zoster disease by a health care provider; or laboratory evidence of immunity or laboratory confirmation of disease.

# Human papillomavirus (HPV) vaccination
- Three HPV vaccines are licensed for use in females (bivalent HPV vaccine , quadrivalent HPV vaccine , and 9-valent HPV vaccine ) and two HPV vaccines are licensed for use in males (4vHPV and 9vHPV). - For females, 2vHPV, 4vHPV, or 9vHPV is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 26 years, if not previously vaccinated. - For males, 4vHPV or 9vHPV is recommended in a 3-dose series for routine vaccination at age 11 or 12 years and for those aged 13 through 21 years, if not previously vaccinated. Males aged 22 through 26 years may be vaccinated. - HPV vaccination is recommended for men who have sex with men through age 26 years who did not get any or all doses when they were younger. - Vaccination is recommended for immunocompromised persons (including those with HIV infection) through age 26 years who did not get any or all doses when they were younger. - A complete HPV vaccination series consists of 3 doses. The second dose should be administered 4-8 weeks (minimum interval of 4 weeks) after the first dose; the third dose should be administered 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of 12 weeks).
- HPV vaccines are not recommended for use in pregnant women. However, pregnancy testing is not needed before vaccination. If a woman is found to be pregnant after initiating the vaccination series, no intervention is needed; the remainder of the 3-dose series should be delayed until completion or termination of pregnancy.

# Zoster vaccination
- A single dose of zoster vaccine is recommended for adults aged 60 years regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged 50 years, ACIP recommends that vaccination begin at age 60 years. - Persons aged 60 years with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiency.

# Measles, mumps, rubella (MMR) vaccination
- Adults born before 1957 are generally considered immune to measles and mumps.
All adults born in 1957 or later should have documentation of 1 or more doses of MMR vaccine unless they have a medical contraindication to the vaccine or laboratory evidence of immunity to each of the three diseases. Documentation of provider-diagnosed disease is not considered acceptable evidence of immunity for measles, mumps, or rubella. heart failure and cardiomyopathies, excluding hypertension), chronic lung disease (including chronic obstructive lung disease, emphysema, and asthma), chronic liver disease (including cirrhosis), alcoholism, or diabetes mellitus, or who smoke cigarettes: administer PPSV23. At age 65 years, administer PCV13 at least 1 year after PPSV23, followed by another dose of PPSV23 at least 1 year after PCV13 and at least 5 years after the last dose of PPSV23. - Routine pneumococcal vaccination is not recommended for American Indian/ Alaska Native or other adults unless they have an indication as above; however, public health authorities may consider recommending the use of pneumococcal vaccines for American Indians/Alaska Natives or other adults who live in areas with increased risk for invasive pneumococcal disease.

# Hepatitis A vaccination
- Vaccinate any person seeking protection from hepatitis A virus (HAV) infection and persons with any of the following indications:
men who have sex with men; -persons who use injection or noninjection illicit drugs; -persons working with HAV-infected primates or with HAV in a research laboratory setting; -persons with chronic liver disease and persons who receive clotting factor concentrates; -persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A (see footnote 1); and unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity of hepatitis A (see footnote 1). The first dose of the 2-dose hepatitis A vaccine series should be administered as soon as adoption is planned, ideally 2 or more weeks before the arrival of the adoptee. - Single-antigen vaccine formulations should be administered in a 2-dose schedule at either 0 and 6-12 months (Havrix), or 0 and 6-18 months (Vaqta). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, administer 3 doses at 0, 1, and 6 months; alternatively, a 4-dose schedule may be used, administered on days 0, 7, and 21-30 followed by a booster dose at 12 months.

# Hepatitis B vaccination
- Vaccinate any person seeking protection from hepatitis B virus (HBV) infection and persons with any of the following indications:
sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than 1 sex partner during the previous 6 months); persons seeking evaluation or treatment for a sexually transmitted disease (STD); current or recent injection drug users; and men who have sex with men; -health care personnel and public safety workers who are potentially exposed to blood or other infectious body fluids; -persons who are aged <60 years with diabetes as soon as feasible after diagnosis; persons with diabetes who are aged 60 years at the discretion of the treating clinician based on the likelihood of acquiring HBV infection, including the risk posed by an increased need for assisted blood glucose monitoring in long-term care facilities, the likelihood of experiencing chronic sequelae if infected with HBV, and the likelihood of immune response to vaccination; -persons with end-stage renal disease (including patients receiving hemodialysis), persons with HIV infection, and persons with chronic liver disease; -household contacts and sex partners of hepatitis B surface antigenpositive persons, clients and staff members of institutions for persons with developmental disabilities, and international travelers to regions with high or intermediate levels of endemic HBV infection (see footnote 1); and all adults in the following settings: STD treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and prevention services, health care settings targeting services to injection drug users or men who have sex with men, correctional facilities, end-stage renal disease programs and facilities for chronic hemodialysis patients, and institutions and nonresidential day care facilities for persons with developmental disabilities. - Administer missing doses to complete a 3-dose series of hepatitis B vaccine to those persons not vaccinated or not completely vaccinated. The second dose should be administered at least 1 month after the first dose; the third dose should be administered at least 2 months after the second dose (and at least 4 months after the first dose). If the combined hepatitis A and hepatitis B vaccine (Twinrix) is used, give 3 doses at 0, 1, and 6 months; alternatively, a 4-dose Twinrix schedule may be used, administered on days 0, 7, and 21-30, followed by a booster dose at 12 months. - Adult patients receiving hemodialysis or with other immunocompromising conditions should receive 1 dose of 40 mcg/mL (Recombivax HB) administered on a 3-dose schedule at 0, 1, and 6 months or 2 doses of 20 mcg/mL (Engerix-B) administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months.

# Meningococcal vaccination
- - First-year college students aged 21 years who live in residence halls: administer a single dose of MenACWY vaccine if they have not received a dose on or after their 16 th birthday. - Young adults aged 16 through 23 years (preferred age range is 16 through 18 years): may be vaccinated with a series of MenB vaccine to provide short-term protection against most strains of serogroup B meningococcal disease.

# Haemophilus influenzae type b (Hib) vaccination
- One dose of Hib vaccine should be administered to persons who have anatomical or functional asplenia or sickle cell disease or are undergoing elective splenectomy if they have not previously received Hib vaccine. Hib vaccination 14 or more days before splenectomy is suggested. - Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6-12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses. - Hib vaccine is not recommended for adults with HIV infection since their risk for Hib infection is low.

# Immunocompromising conditions
- Inactivated vaccines (e.g., pneumococcal, meningococcal, and inactivated influenza vaccines) generally are acceptable and live vaccines generally should be avoided in persons with immune deficiencies or immunocompromising conditions. Information on specific conditions is available at www.cdc.gov/ vaccines/hcp/acip-recs/index.html.